3 Turnaround Candidates for 2018 You Should Consider Now

Beleaguered companies such as Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and others could stand to finally see a turnaround in 2018.

| More on:

Everyone loves a comeback story.

The market is full of them, and it’s during this end-of-year frenzy, between turkey dinners with family, that investors look towards next year and determine if some former greats could turn around.

Here are a few options to consider moving into 2018.

There’s no better stock that comes to mind when thinking of “epic collapse” than Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). The former darling of the market once had a market cap that exceeded some of Canada’s big banks before tumbling over 90% two years ago.

There are multiple reasons for that epic collapse, but a big one was that Valeant had a flawed business model that was overly reliant on cheap debt. When the stock finally tanked, Valeant was left with a broken business model, over US$30 billion in debt, and a stock price that left investors shaking their heads in disbelief.

Why is Valeant a good option now? Valeant’s new management team, headed by CEO Joseph Papa has not only begun to clean up the mess left by others, but it’s using a proper business model that is not entirely fueled on cheap loans. The company has also aggressively focused on debt reduction, selling non-core assets to pay down the mountain of debt.

Valeant is on track to finish 2017 on an impressive run with a stock price that is up year to date by 40%.

Cameco Corp. (TSX:CCO)(NYSE:CCJ) is another interesting turnaround target that is beginning to gain steam. Cameco is one of the largest uranium miners in the world, providing fuel for nuclear power plants.

The problem with Cameco is that when the Fukushima reactor in Japan was damaged following an earthquake-induced tsunami in 2011, world demand for uranium effectively dried up. This left Cameco and other uranium miners extracting uranium (for a significant cost) that nobody was buying. As the price continued to drop, and supplies continued to increase, a glut was formed that kept prices low, which was, thankfully, not entirely felt by Cameco due to the nature of long-term uranium purchase agreements.

There are two reasons to be optimistic about Cameco in 2018. First, Cameco and other leading uranium miners have announced a series of significant production cuts recently that will clear the supply glut and hopefully see prices begin to rise. The second reason has to do with demand, which is steadily growing thanks to a flurry of new construction and infrastructure development across the developing nations of Asia.

BlackBerry Ltd. (TSX:BB)(NYSE:BB) is another perennial turnaround candidate, which is arguably in the latter phases of its transformation. The company once had the leading market share of smartphones around the world, at least until both Android and iOS gobbled up that market share and reduced BlackBerry’s usage to little more than a rounding error.

Today, the company has little in common with its former self apart from a strong desire and industry-leading knowledge on security. BlackBerry no longer makes devices itself; rather, it licenses third parties to manufacture and market the devices.

BlackBerry’s real potential in 2018 and beyond lies in another area: automation. The company’s IoT asset-tracking solution holds promise, and the brain behind BlackBerry’s failed proprietary BB10 platform, QNX, is a key component to the future of autonomous driving; it’s already installed in over 60 million vehicles worldwide.

Year to date, BlackBerry has soared nearly 60%, and 2018 looks to be even more promising, as the company has finally returned to profitability.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of BlackBerry and Valeant Pharmaceuticals. BlackBerry is a recommendation of Stock Advisor Canada.

More on Tech Stocks

Family relationship with bond and care
Dividend Stocks

TFSA Investors: 3 Cheap Canadian Stocks for Retirees

These three Canadian stocks are super cheap for retirees looking for a great buy that will last the test of…

Read more »

consider the options
Tech Stocks

Better Buy (2024 Edition): Shopify or Nvidia Stock?

Shopify (TSX:SHOP) isn't the only red-hot tech stock in town that could add to recent gains.

Read more »

Illustration of bull and bear
Tech Stocks

A Bull Market Is Coming: 3 Growth Stocks That Could Thrive

Given their high growth prospects and cheaper valuation, these three growth stocks would be an excellent buy as the market…

Read more »

online shopping
Tech Stocks

2 Stocks That Saw Major Black Friday Boosts

These stocks saw a pretty amazing Black Friday, a sign that both are probably going to be a great buy…

Read more »

Growing plant shoots on coins
Tech Stocks

2 Top Growth Stocks in Canada for December 2023

Here are two of the best Canadian growth stocks you can buy in December 2023.

Read more »

Dots over the earth connecting the world
Tech Stocks

Is Constellation Software Stock Worth a Buy in December?

Constellation stock (TSX:CSU) is up 46% in the last year alone, but after an earnings miss should investors still consider…

Read more »

Man data analyze
Tech Stocks

Beyond SPY Stock: Top U.S. Picks for Canadian Investors

Venturing beyond SPY stock opens up a world of investment possibilities for Canadian investors. Top U.S. picks include Apple.

Read more »

edit Colleagues chat over ketchup chips
Tech Stocks

Is Now the Right Time to Buy Tech Stocks Trading Cheaply?

Tech stocks are still cheap across the board, but these two are the best of the best in my view,…

Read more »